Search

Author/Creator Wagner, Lily

1. Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis. Issue 4 (17th January 2023)

Authors:
Meier, Juris J.; Bardtrum, Lars; Cheng, Alice Y. Y.; Malling, Brian; Montanya, Eduard; Wagner, Lily; Pratley, Richard E.
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 25:Issue 4(2023)
Page Start:
1130
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial. (1st January 2021)

Authors:
Tarride, Jean-Eric; Husain, Mansoor; Andersen, Andreas; Gundgaard, Jens; Luckevich, Maria; Mark, Thomas; Wagner, Lily; Pieber, Thomas R.
Journal:
Journal of medical economics
Issue:
Volume 24:Number 1(2021)
Page Start:
1318
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial. Issue 2 (17th October 2021)

Authors:
Pieber, Thomas R.; Bajaj, Harpreet S.; Heller, Simon R.; Jia, Ting; Khunti, Kamlesh; Klonoff, David C.; Ladelund, Steen; Leiter, Lawrence A.; Wagner, Lily; Philis‐Tsimikas, Athena
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 24:Issue 2(2022)
Page Start:
332
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗